Completed PHASE2 INTERVENTIONAL 1-arm NCT04475016

TIP (Paclitaxel + Ifosfamide + Cisplatin) Combined With Nimotuzumab & Triprilimab as Neoadjuvant Treatment in Locally Advanced Penile Cancer

A Single Center and Single Arm Study of TIP (Paclitaxel + Ifosfamide + Cisplatin) Combined With Nimotuzumab & Triprilimab as Neoadjuvant Treatment in Locally Advanced Penile Cancer

Sponsor: Sun Yat-sen University

Conditions Penile Cancer

Interventions Albumin-Bound Paclitaxel Cisplatin Ifosfamide Nimotuzumab Triprilimab

Updated 6 times since 2020 Last updated: Jun 8, 2022 Started: Aug 12, 2020 Primary completion: May 6, 2022 Completion: May 30, 2022

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Penile Cancer and is currently completed. Sun Yat-sen University leads this study, which shows 6 recorded versions since 2020 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jul 2022 — Jul 2024 [monthly]

Completed PHASE2

Status: Recruiting → Completed
Jan 2021 — Jul 2022 [monthly]

Recruiting PHASE2
Sep 2020 — Jan 2021 [monthly]

Recruiting PHASE2

Status: Not Yet Recruiting → Recruiting

▶ Show 1 earlier version

Aug 2020 — Sep 2020 [monthly]

Not Yet Recruiting PHASE2

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Sun Yat-sen University

Data source: Sun Yat-sen University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Guangzhou, China